On 2014 Apr 24, Christine Houghton commented:

This paper misquotes the scientific literature in a manner that one might be associated with the declared commercial interest. The issue in summary is this:

1. NuSkin sells a product named ‘AgeLOC’ which contains 3 ingredients as a proprietary blend totalling 450 mg; one of those ingredients is Broccoli Seed Extract.
2. Whole broccoli sprouts contain a precursor compound, glucoraphanin and an enzyme, myrosinase, compartmentalised within the plant cell. When the cell is ruptured, the enzymatic reaction occurs, yielding the bioactive compound, sulforaphane (SFN).
3. The Broccoli Seed 'Extract' is known to be devoid of the myrosinase enzyme necessary for sulforaphane to be generated. Broccoli Seed Extract is a source ONLY of the precursor compound, glucoraphanin.
4. The authors discuss at length the science of SFN including its potential therapeutic effects, even though the NuSKIN product does not yield SFN. 5.In their Citation #36, they refer to a published clinical trial confirming the therapeutic benefits of broccoli seed.
5. Riedl’s cited study DID NOT use broccoli ‘seed’; Riedl used a fresh broccoli sprout homogenate which was shown to yield SFN. Riedl’s findings can not be used to support the ‘extract'.
6. Riedl’s paper has been misquoted, claiming benefits for seed extract that the study did not demonstrate.
7. The authors also refer to the essentiality of the myrosinase enzyme for SFN to be formed; they claim it is present in the seed or produced by the human intestine.
8. Whilst there is some evidence that an uncertain group of colonic microflora do have some myrosinase activity, the effect has been shown to be small and highly-variable across individuals.

Even though the authors declare their commercial interest, a reader may therefore incorrectly assume that the biochemistry discussed at length in the paper supports the products marketed by the company.

On 2014 Apr 24, Christine Houghton commented:

This paper misquotes the scientific literature in a manner that one might be associated with the declared commercial interest. The issue in summary is this:

1. NuSkin sells a product named ‘AgeLOC’ which contains 3 ingredients as a proprietary blend totalling 450 mg; one of those ingredients is Broccoli Seed Extract.
2. Whole broccoli sprouts contain a precursor compound, glucoraphanin and an enzyme, myrosinase, compartmentalised within the plant cell. When the cell is ruptured, the enzymatic reaction occurs, yielding the bioactive compound, sulforaphane (SFN).
3. The Broccoli Seed 'Extract' is known to be devoid of the myrosinase enzyme necessary for sulforaphane to be generated. Broccoli Seed Extract is a source ONLY of the precursor compound, glucoraphanin.
4. The authors discuss at length the science of SFN including its potential therapeutic effects, even though the NuSKIN product does not yield SFN. 5.In their Citation #36, they refer to a published clinical trial confirming the therapeutic benefits of broccoli seed.
5. Riedl’s cited study DID NOT use broccoli ‘seed’; Riedl used a fresh broccoli sprout homogenate which was shown to yield SFN. Riedl’s findings can not be used to support the ‘extract'.
6. Riedl’s paper has been misquoted, claiming benefits for seed extract that the study did not demonstrate.
7. The authors also refer to the essentiality of the myrosinase enzyme for SFN to be formed; they claim it is present in the seed or produced by the human intestine.
8. Whilst there is some evidence that an uncertain group of colonic microflora do have some myrosinase activity, the effect has been shown to be small and highly-variable across individuals.

Even though the authors declare their commercial interest, a reader may therefore incorrectly assume that the biochemistry discussed at length in the paper supports the products marketed by the company.